Truist Securities on Beta Bionics, Inc. (BBNX): 'MINT Launch The Key Catalyst & On Track For 1Q27'

October 28, 2026 4:28 AM

Truist Securities analyst Richard Newitter reiterated a Buy rating and $28.00 price target on Beta Bionics, Inc. (NASDAQ: BBNX).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found